Novonesis stock (DK0060336014): Integration of Novozymes and Chr. Hansen reshapes enzyme leader

Biotech group Novonesis, formed from the merger of Novozymes and Chr. Hansen, is progressing with its integration and cost synergies while navigating volatile markets and mixed sentiment among European investors.

Novonesis, the combined biosolutions group created from the merger of Novozymes and Chr. Hansen, continues to execute its integration program and synergy plans while investors digest the new structure and outlook for the enlarged enzyme and microbial solutions specialist, according to recent company updates and European market coverage in April and May 2025 from Novonesis investor relations as of 04/25/2025 and Euronext Copenhagen as of 05/20/2025.

As of: 09.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novonesis
• Sector/industry: Biotechnology, industrial enzymes and microbial solutions
• Headquarters/country: Denmark
• Core markets: Food and beverages, household care, agriculture, bioenergy and industrial applications
• Key revenue drivers: Enzymes and microbial solutions for food, detergents, biofuels and agriculture
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: NSIS B)
• Trading currency: Danish krone (DKK)

Novonesis: core business model

Novonesis positions itself as a global biosolutions group with a focus on enzymes, probiotics and microbial technologies that improve efficiency and sustainability in industrial and consumer applications, based on the combined legacy of Novozymes and Chr. Hansen described in merger communications from early 2024 by Novonesis news as of 01/29/2024.

The company generates most of its revenue from selling specialty ingredients and solutions to large manufacturers in food and beverages, household care, bioenergy and agriculture, rather than from end-consumer brands, according to product overviews in the group’s business description issued alongside the 2024 annual report by Novonesis reports as of 02/07/2025.

In its 2024 annual report published in February 2025, Novonesis highlighted that a significant share of sales stems from recurring, long-term customer relationships and application-specific solutions, which can support relatively resilient demand even in volatile macro environments, as noted by Novonesis annual report 2024 as of 02/07/2025.

The merger was framed as a way to combine complementary technology platforms in enzymes and microbial solutions, with management pointing to a broader innovation pipeline and cross-selling opportunities across food, agriculture and household care, according to the merger completion announcement in January 2024 from Novonesis merger update as of 01/29/2024.

At the same time, the business model remains asset-light compared with traditional chemical manufacturers, with a focus on intellectual property, fermentation expertise and application know-how rather than heavy capital-intensive production, as outlined in the company’s strategic presentation for investors released in March 2025 by Novonesis investor presentation as of 03/18/2025.

Main revenue and product drivers for Novonesis

Food and beverages represent one of the largest revenue contributors for Novonesis, with solutions that help improve yield, texture, flavor and shelf life in dairy, baking and other food categories, according to segment disclosures in the 2024 annual report published in February 2025 by Novonesis annual report 2024 as of 02/07/2025.

Household care is another key driver, where enzymes enable lower-temperature washing and reduced water and energy use in laundry and dishwashing detergents, a theme the company highlighted as a sustainability lever in its 2024 sustainability report issued in April 2025 by Novonesis sustainability report 2024 as of 04/11/2025.

Bioenergy, particularly enzymes for starch-based ethanol and advanced biofuels, remains a cyclical but important business, with demand linked to fuel-blending mandates and relative energy prices, as discussed in management’s review of the bioenergy segment in the 2024 annual report from Novonesis annual report 2024 as of 02/07/2025.

Agriculture and animal health, including microbial solutions for crop protection and animal probiotics, are another growth area, with the company citing rising demand for biological alternatives to conventional chemicals in its March 2025 capital markets presentation presented by Novonesis investor presentation as of 03/18/2025.

Geographically, Novonesis generates revenue across Europe, North America and emerging markets, with the company indicating that the United States remains one of its largest single-country markets, particularly in bioenergy, household care and food ingredient applications, according to regional breakdowns in the 2024 annual report published in February 2025 by Novonesis annual report 2024 as of 02/07/2025.

Conclusion

Novonesis has emerged as a scaled player in industrial enzymes and microbial solutions following the merger of Novozymes and Chr. Hansen, with management emphasizing cost synergies, a broader innovation pipeline and exposure to long-term sustainability trends in sectors such as detergents, bioenergy and food, based on statements in the 2024 annual report and capital markets materials from Novonesis investor relations as of 03/18/2025.

At the same time, the stock trades in a sector that can be sensitive to industrial production, consumer spending and energy markets, while integration execution, realized synergies and organic growth in key end-markets remain central factors that investors monitor, according to commentary from European financial media covering the name in May 2025, including Euroinvestor as of 05/20/2025.

For US-focused investors, Novonesis can be seen as an international exposure to biotechnology-based industrial solutions with substantial revenue links to North American customers, but also to European regulation, currency movements and the competitive dynamics of global specialty ingredients markets, without any view here on whether the stock is attractive, expensive or fairly valued.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.